Martin, A M
Nirschl, T R
Nirschl, C J
Francica, B J
Kochel, C M
van Bokhoven, A
Meeker, A K
Lucia, M S
Anders, R A
DeMarzo, A M
Drake, C G
Article History
Received: 29 April 2015
Revised: 29 June 2015
Accepted: 8 July 2015
First Online: 11 August 2015
Competing interests
: CGD has consulted for Amplimmune, Bristol Myers Squibb (BMS), Merck and Roche-Genentech, all of whom have either anti-PD-1 or anti-PD-L1 reagents in various stages of clinical development. In addition, Drs Anders and Drake have received sponsored research funding from BMS. The first author Dr Martin has no conflict of interest to declare. All the other authors declare no conflict of interest.